Medical equipment and pharmaceutical supplier McKesson (NYSE: MCK) is set to report earnings on January 31. While investors wait for the earnings results, the stock is facing resistance in the form of the upper rail of a downward sloped trend channel. The channel started back in late April and connects the highs from then, June, October, and November. The lower rail connects the lows from April, July/August, and December.
If the resistance holds and the stock makes another trip down to the lower rail, it would put the stock down below the $100 mark. McKesson hasn’t been under $100 since early 2013, but the trend has been to the downside since the stock hit an all-time high of $236.52 back in May 2015.
The company’s fundamentals are mixed with a decent return on equity, but slow earnings growth, sales growth, and a low profit margin. The company’s ROE is 25.3% and that is the highlight among the fundamental indicators. Earnings have only grown at a rate of 2% per year over the last three years while sales have grown at a rate of 4% during that same timeframe. It isn’t helping earnings that the company sports a profit margin of only 1.7%.
MCK's Aroon Indicator triggered a bullish signal on December 01, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 327 similar instances where the Aroon Indicator showed a similar pattern. In of the 327 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on November 21, 2025. You may want to consider a long position or call options on MCK as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MCK advanced for three days, in of 384 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for MCK moved out of overbought territory on November 28, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 54 similar instances where the indicator moved out of overbought territory. In of the 54 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 74 cases where MCK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MCK turned negative on December 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MCK broke above its upper Bollinger Band on November 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (9.681). P/E Ratio (26.786) is within average values for comparable stocks, (30.786). Projected Growth (PEG Ratio) (1.035) is also within normal values, averaging (2.605). Dividend Yield (0.004) settles around the average of (0.029) among similar stocks. P/S Ratio (0.278) is also within normal values, averaging (141.635).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MCK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a distributer of pharmaceuticals and provides healthcare software and health information technology services
Industry MedicalDistributors